Lion Point Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Lion Point Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$841K	Hold	36,000	–	–	5.03%	6
2025 Q4	$756K	Sell	36,000 -19,000	-35%	-$331K	3.91%	9
2025 Q3	$846K	Hold	55,000	–	–	4.81%	10
2025 Q2	$515K	Hold	55,000	–	–	3.5%	14
2025 Q1	$676K	Hold	55,000	–	–	4.31%	11
2024 Q4	$727K	Buy	55,000 +8,800	+19%	+$151K	3.81%	11
2024 Q3	$889K	Sell	46,200 -18,800	-29%	-$388K	1.98%	13
2024 Q2	$1.33M	Hold	65,000	–	–	2.43%	10
2024 Q1	$1.55M	Buy	65,000 +30,500	+88%	+$680K	0.86%	12
2023 Q4	$746K	Hold	34,500	–	–	0.37%	16
2023 Q3	$501K	Hold	34,500	–	–	0.22%	24
2023 Q2	$722K	Buy	+34,500	New	+$718K	0.33%	20

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Lion Point Capital's SNDX Position: Q1 2026 in Review

Lion Point Capital held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 36,000 shares worth $841K. The position accounts for 5.03% of the portfolio, ranked #6.

Lion Point Capital first reported a position in SNDX in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.55M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

Lion Point Capital held 36,000 shares of Syndax Pharmaceuticals worth $841K as of Q1 2026.
Lion Point Capital left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
Syndax Pharmaceuticals made up 5.03% of Lion Point Capital's portfolio in Q1 2026, its #6 holding.
Lion Point Capital first reported a position in Syndax Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Lion Point Capital's Syndax Pharmaceuticals position peaked at $1.55M in Q1 2024.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Lion Point Capital's 13F filing for Q1 2026, filed 15 May 2026.